- Home
- SBRA vs LQDA Comparison
SBRA vs LQDA Comparison
Compare SBRA & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SBRA | LQDA |
|---|---|---|
| Founded | 2010 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 5.5B |
| IPO Year | 2010 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SBRA | LQDA |
|---|---|---|
| Price | $19.18 | $27.76 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 8 |
| Target Price | $22.79 | ★ $107.75 |
| AVG Volume (30 Days) | ★ 2.0M | 950.7K |
| Earning Date | 11-04-2026 | 11-02-2026 |
| Dividend Yield | ★ 6.08% | N/A |
| EPS Growth | 18.52 | ★ 51.81 |
| EPS | 0.06 | ★ 1.26 |
| Revenue | ★ $774,632,000.00 | $158,320,000.00 |
| Revenue This Year | $19.97 | $366.74 |
| Revenue Next Year | $8.18 | $65.90 |
| P/E Ratio | $330.58 | ★ $56.05 |
| Revenue Growth | 10.15 | ★ 1031.18 |
| 52 Week Low | $17.17 | $21.91 |
| 52 Week High | $22.81 | $93.61 |
Technical Indicators
Market Signals| Indicator | SBRA | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 30.47 | 18.20 |
| Support Level | $19.35 | N/A |
| Resistance Level | $20.62 | $39.26 |
| Average True Range (ATR) | 0.34 | 3.29 |
| MACD | -0.06 | -2.08 |
| Stochastic Oscillator | 0.00 | 5.95 |
Price Performance
Historical ComparisonAbout SBRA Sabra Health Care REIT Inc.
Sabra Health Care REIT Inc is a healthcare facility real estate investment trust. The company operates one segment that owns and invests in healthcare real estate. All of the company's revenue is generated in the United States. Sabra's operations consist of nursing facilities, assisted living centers, and mental health facilities.
About LQDA Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.